Search | Clinical Trials Finder

Conditions: Autoimmune Inner Ear Disease, Meniere's Disease
Interventions: Anakinra 100Mg/0.67Ml Inj Syringe (Period 1), Placebo injection (Period 1), Anakinra 100Mg/0.67Ml Inj Syringe (Period 2), Placebo injection (Period 2); Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Influenza
Interventions: Investigational H9N2 vaccine GSK2654911A, Investigational H9N2 vaccine GSK2654909A, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 422 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Miami, Florida • Edison, New Jersey • Austin, Texas

Conditions: Laryngeal Stenosis, Subglottic Stenosis, Tracheal Stenosis
Interventions: Mitomycin -C, Saline application; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy Volunteers
Interventions: VRG50635, Placebo; Drug
Lead sponsor: Verge Genomics; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Progressive Supranuclear Palsy (PSP)
Interventions: antisense oligonucleotide, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: La Jolla, California • Rochester, Minnesota • Nashville, Tennessee

Conditions: Schizophrenia
Interventions: ITI-214 Dose A, ITI-214 Dose B, ITI-214 Dose C, ITI-214 Dose D (Elderly), Placebo, ITI-214 Dose E, ITI-214 Dose F, ITI-214 Dose G, ITI-214 Dose H; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Glendale, California • New York, New York

Conditions: Narcolepsy Type 1
Interventions: TAK-360, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Redwood City, California • Miami, Florida • Cincinnati, Ohio

Conditions: Chronic Low-back Pain
Interventions: Spinal Manipulation Therapy (SMT), Naloxone, Placebo, Mindfulness Based Stress Reduction Therapy (MT); Other · Drug · Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • Nashville, Tennessee

Conditions: Influenza
Interventions: Placebo, Favipiravir; Drug
Lead sponsor: MDVI, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Acromegaly
Interventions: MAR002, Placebo; Drug
Lead sponsor: Marea Therapeutics; Industry
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Hyperlipidemia
Interventions: LY3015014 IV, Placebo IV, LY3015014 SC, Placebo SC; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Glendale, California • Dallas, Texas • Madison, Wisconsin

Conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions: 15 mg sodium nitrite inhalation solution, 90 mg sodium nitrite inhalation solution, 45 mg sodium nitrite inhalation solution, 120 mg sodium nitrite inhalation solution, 25% MTD sodium nitrite inhalation solution; Drug
Lead sponsor: Aires Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 56 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatitis C
Interventions: ACH-0141625 (Sovaprevir), Placebo, Pegylated Interferon alpha-2a, Ribavirin; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Bradenton, Florida + 11 more

Conditions: Pulmonary Function; Newborn, Abnormal, Infant Wheeze, In-utero Nicotine, Second Hand Smoke
Interventions: Vitamin C +prenatal vitamin, Placebo tablet+prenatal vitamin; Dietary Supplement
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 15 Years and older · Female only
Enrollment: 252 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Indianapolis, Indiana • Portland, Oregon

Conditions: Healthy
Interventions: Y-2 Sublingual Tablet, Placebo; Drug
Lead sponsor: Simcere Pharmaceutical Co., Ltd; Other
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy
Interventions: IA-14069, Placebo; Drug
Lead sponsor: ILAb Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy Volunteers
Interventions: C16TR, Placebo, Tyvaso®; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hyperlipidaemia
Interventions: AZD8233, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 16
States / cities: Huntsville, Alabama • Canoga Park, California • Lincoln, California + 12 more

Conditions: Healthy Volunteer, HIV Vaccine
Interventions: Ad4-mgag, Ad4-EnvC150, Placebo Comparator, AIDSVAX B/E; Biological · Other
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Hypertension
Interventions: Omega 3, Placebo; Dietary Supplement · Other
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Asthma
Interventions: PF-07275315, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 36
States / cities: Mobile, Alabama • Chandler, Arizona • Lancaster, California + 29 more

Conditions: Hypercholesterolemia, Dyslipidemia
Interventions: Placebo, PF-04950615 (RN316); Other · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 29
States / cities: Birmingham, Alabama • Garden Grove, California • Long Beach, California + 18 more

Conditions: Obesity
Interventions: LY3532226, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin icodec, Placebo (insulin 287), Metformin, Dipeptidyl peptidase-4 inhibitors, Insulin glargine, Placebo (insulin glargine); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 14
States / cities: Lancaster, California • Ventura, California • Walnut Creek, California + 9 more

Search by objective public record fields.

Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age

Study of Mitomycin-C Application in Laryngotracheal Stenosis

A Study of VRG50635 in Healthy Volunteers

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy

Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia

A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)

Efficacy of Spinal Manipulation Therapy or Mindfulness-based Reduction Therapy on Patients With Chronic Low Back Pain

T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza

Study of MAR002 in Healthy Men

A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol

Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects

Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function

A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of Y-2 Sublingual Tablet in Healthy Adult Subjects

SAD Study of IA-14069

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants

A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia

Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults

Heat Therapy and Omega 3 on Cardio-Metabolic Health

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

A Study of LY3532226 in Participants With Obesity

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.